We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Traitements systémiques de première ligne des cancers avancés des voies biliaires.
- Authors
Jary, Marine; Assenat, Éric; Delaye, Matthieu; Blanc, Jean-Frédéric; Lièvre, Astrid
- Abstract
In 2010, the combination of cisplatin + gemcitabine (CISGEM) showed its -superiority over gemcitabine alone in first-line treatment of advanced biliary tract cancers (BTC) in the ABC-02 trial. For more than 10 years, no study then showed a benefit in intensifying chemotherapy or combining targeted therapy with CISGEM. Recently, a step was finally taken with the demonstration of the benefit provided by the addition of an immunotherapy to CISGEM, first durvalumab in the TOPAZ-1 study (the new standard of care in first-line) then pembrolizumab in the KEYNOTE-966 trial. BTC contain frequent molecular alterations whose therapeutic targeting has already been demonstrated to be effective in 2nd line or higher and could also be interesting in the first line in the future.
- Subjects
BILIARY tract cancer; GEMCITABINE; IMMUNOTHERAPY
- Publication
Hépato-Gastro & Oncologie Digestive, 2023, Vol 30, Issue 10, p1035
- ISSN
2115-3310
- Publication type
Article
- DOI
10.1684/hpg.2023.2684